Martin W. Oster, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: The new anti-emetic agent, ondansetron (Zofran; Glaxo Inc., Research Triangle Park, North Carolina) appears to be a major step forward in eliminating cancer chemotherapy-induced nausea and vomiting (1). However, a problem with ondansetron has been its recommended method of administration, which is 0.15 mg/kg body weight by intravenous infusion every 4 hours for three doses, starting 30 minutes before the chemotherapy is given. This method of administration is inconvenient for outpatients whose chemotherapy may only take 30 to 60 minutes to administer. For that reason, I wish to report that I have found a more convenient method
Oster MW. Oral Ondansetron. Ann Intern Med. 1991;115:233. doi: 10.7326/0003-4819-115-3-233_2
Download citation file:
Published: Ann Intern Med. 1991;115(3):233.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use